Welcome to IMMUTRAIN


This project has received funding from the European Union’s Horizon 2020 research and

innovation programme under the Marie Sklodowska-Curie grant agreement No 641549


Immutrain_map Kopie


In the European Union, cancer is the leading cause of death and the overall cancer incidence is still increasing. As a result of expanding efforts to improve cancer outcome, a main paradigm change is occurring in cancer therapy towards individualized medicine. Antibody-based therapies form an integral and constantly growing part of this approach. Antibody-based therapies will strongly influence the coming decade of cancer care. The importance of immunotherapy has been highlighted by the prestigious Science journal as “breakthrough of the year 2013”, heralding the rising importance of immunotherapy. Accordingly the need for well-trained and skilled researchers in academia and industry is dramatically increasing in this field. IMMUTRAIN is a training network bringing together experts in the fields of monoclonal antibodies, dendritic cells, T-cells and immunomodulatory nucleic acids with a considerable industrial involvement. The network comprises nine academic research groups and five industrial partners in a total of nine European countries. IMMUTRAIN will actively create synergies between those sectors by forming and promoting young researchers to match the challenges of immunotherapies. Particular focus will be placed on combinatorial therapies and on the new emerging field of bispecific antibodies used to target both the tumor and the patient´s immune system. Fifteen Ph. D. students (early stage researchers, ESR) reinforced by the project leaders will investigate innovative therapeutic strategies and provide the rationale for future clinical trials. Throughout their projects, ESR will learn to integrate academic and industrial aspects and will sharpen their experimental and complementary skills in a well-designed and diversified training program.

Available Positions

15 positions as Early Stage Researcher (PhD student) in the field of Cancer Immunotherapy The overall scientific objective of IMMUTRAIN is to enhance the efficacy of antibody-based therapies through combination with other immunotherapeutic approaches. IMMUTRAIN offers a considerable industrial and academic involvement to train the next generation of scientists from different perspectives in the field of Immunotherapy of Cancer. Further Information: www.immutrain.eu We offer: cutting edge research projects integrated in one of the four work packages (WP) of IMMUTRAIN and training with the leading experts in the field of Immunotherapy for Cancer; opportunities for future employment; employment contract for three years with all the benefits of the Marie Skłodowska-Curie programme; We seek: Excellent scientists with a master degree or equivalent in natural sciences or related disciplines (such as medicine or pharmacy); Practical skills in modern laboratory work, preferentially combined with experience in animal experiments. You must: Be within your first four years of research experience after completion of your masters degree or equivalent; Not hold a doctoral degree at the time of recruitment; Not have spent more than 12 months within the past 36 months in the country where the institution you are applying for is located; Be proficient in the English language both written and spoken (proof required), Open positions: - WP1, Combination of antibodies with adoptive T cell transfer: ESR 1 and ESR 2 (Ludwig-Maximilians-Universität, Germany), ESR 3 (Nottingham Trent University, UK), ESR 4 and ESR 5 and ESR5 (University Hospital Herlev, Region Hovedstaden, Denmark) - WP2, New formulations of antibodies to activate immune cells: ESR 6 (Ludwig-Maximilians-Universität, Germany), ESR 7 (Roche Diagnostics GmbH, Germany), ESR8 (Istituto Europeo di Oncologia, Italy) - WP3, Combination of antibodies with dendritic cell therapy: ESR 9 (Radboud University Medical Centre, Netherlands), ESR 10 (Medical University of Innsbruck, Austria) - WP4, Combination of antibodies with therapeutic nucleid acids: ESR 11 (Institut Gustave Roussy, France), ESR 12 (Université de Fribourg, Switzerland), ESR 13 (Ludwig-Maximilians Universität München, Germany), ESR 14 and ESR 15 (Spanish National Cancer Research Center) Application: The application procedure will be carried out in compliance with the Code of Conduct for Recruitment and the Charter for Researchers. Applications can be sent until March, 4 to http://portal.graduatecenter-lmu.de/ocgc/itn-immutrain [mehr...]